Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 USD | -4.74% | -13.40% | +124.15% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+124.15% | 838M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.54% | 22.78B | |
-10.93% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics Gets FDA Approval for Seborrheic Dermatitis Treatment -- Shares Surge Premarket